miconazole oil / Hill Dermaceuticals - LARVOL DELTA

Development of synergistic antifungal in situ gel of miconazole nitrate loaded microemulsion as a novel approach to treat vaginal candidiasis. (PubMed, Sci Rep) - "After incorporation of the selected formulation into a mixture of P407 and P188 (18:2% w/w) with 0.6% mucoadhesive polymer, the resultant MG formulation (MG1) revealed optimum gelation temperature (33 ± 0.01℃) and appropriate viscosity with enhanced sustained release (98%) and retention through sheep vaginal mucosa, MG1 exhibited a better MIZ compared to the 2% MN gel formulation and the marketed MN product, and no rabbit vagina irritation. In conclusion, the miconazole nitrate-loaded MG-based formula sustained the duration of action and better antifungal activity than the marketed miconazole nitrate formulation."

Journal • Candidiasis • Vaginitis

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) (clinicaltrials.gov) - P2/3 | N=382 | Completed | Sponsor: Hill Dermaceuticals, Inc. | Phase classification: P3 ➔ P2/3

Phase classification • Infectious Disease • Otorhinolaryngology

Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis (clinicaltrials.gov) - P3 | N=100 | Recruiting | Sponsor: Hill Dermaceuticals, Inc. | Not yet recruiting ➔ Recruiting | Trial completion date: Nov 2023 ➔ Nov 2024 | Trial primary completion date: Sep 2023 ➔ Sep 2024

Enrollment open • Trial completion date • Trial primary completion date • Otorhinolaryngology

Development of miconazole nitrate nanoparticles loaded in nanoemulgel to improve its antifungal activity. (PubMed, Saudi Pharm J) - "In conclusion, a novel MNZ nanoemulgel showing superior antifungal activity compared to that of the commercial product has been developed. This nanotechnology technique is a step toward making pharmaceutical dosage forms that has a lot of promise."

Journal • Infectious Disease

Phase III Efficacy and Safety Study of Miconazole Oil for Otomycosis (clinicaltrials.gov) - P3 | N=100 | Not yet recruiting | Sponsor: Hill Dermaceuticals, Inc.

New P3 trial • Otorhinolaryngology

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) (clinicaltrials.gov) - P3 | N=382 | Completed | Sponsor: Hill Dermaceuticals, Inc. | Recruiting ➔ Completed

Trial completion • Infectious Disease • Otorhinolaryngology

Development, optimization, and evaluation of a nanostructured lipid carrier of sesame oil loaded with miconazole for the treatment of oral candidiasis. (PubMed, Drug Deliv) - "Additionally, an in vivo efficacy study in terms of the ulcer index against C. albicans found a superior result for the optimized MZ-SO NLC (0.5 ± 0.50) in a treated group of animals. Hence, it can be concluded that MZ, through an optimized NLC of SO, can treat candidiasis effectively by inhibiting the growth of C. albicans."

Journal • Candidiasis

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) (clinicaltrials.gov) - P3; N=390; Recruiting; Sponsor: Hill Dermaceuticals, Inc.; Trial primary completion date: Jul 2021 ➔ Nov 2021

Clinical • Trial primary completion date • Infectious Disease • Otorhinolaryngology

Phytotherapy in the management of denture stomatitis: A systematic review and meta-analysis of randomized controlled trials. (PubMed, Phytother Res) - "There was no difference in the relief of clinical signs (odds ratio (OR) = 0.96; 95% confidence interval (CI): 0.43-2.15) and microbiological improvement (OR = 1.74; 95% CI: 0.55-5.45) between propolis and miconazole. Most of the included studies showed that phytomedicines had fewer side effects and more patient satisfaction than antifungals or disinfectants. However, further RCTs with more standardly prepared herbal formulations are required to verify the clinical efficacy of phytotherapy as an alternative or adjunctive therapy for denture stomatitis."

Journal • Retrospective data • Review • Dental Disorders • Infectious Disease • Stomatitis

Lead optimization generates selenium-containing miconazole CYP51 inhibitors with improved pharmacological profile for the treatment of fungal infections. (PubMed, Eur J Med Chem) - "In addition, molecular docking studies provide a model for the interaction between the compound B17 and the CYP51 protein. Overall, we believe that these selenium-containing miconazole compounds can be further developed for the potential treatment of fungal infections."

Journal • Hematological Disorders • Infectious Disease

Inhibitory Effect of Eugenol and Trans-Anethole Alone and in Combination with Antifungal Medicines on Candida albicans Clinical Isolates. (PubMed, Chem Biodivers) - "Achieved results indicated that eugenol showed synergistic and additive activities with miconazole and econazole against investigated clinical isolates, respectively. We tried to relate the results to changes in C. albicans cell sheaths under the influence of essential oils compounds (EOCs) performing the Fourier transform infrared spectra analysis to confirm the presence of particular chemical moieties in C. albicans cells. Nevertheless, no strong relationships was observed between synergistic and additive actions of used EOC-AMs combinations and chemical moieties in C. albicans cells."

Clinical • Combination therapy • Journal

Miconazole induces autophagic death in glioblastoma cells via reactive oxygen species-mediated endoplasmic reticulum stress. (PubMed, Oncol Lett) - "The inhibition of ER stress via treatment with 4-phenylbutyric acid or BiP knockdown reduced miconazole-induced autophagy and cell death. These findings suggest that miconazole induces autophagic cell death by inducing an ROS-dependent ER stress response in U251MG glioma cancer cells and provide new insights into the potential antiproliferative effects of miconazole."

Journal • Dermatology • Glioblastoma • Glioma • Oncology • Solid Tumor • ERN1

Efficacy and Safety Study of Miconazole Oil Versus Vehicle on Fungal Infection of the Ear Canal (Otomycosis) (clinicaltrials.gov) - P3; N=390; Recruiting; Sponsor: Hill Dermaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open